IDO1 Inhibition Overcomes Radiation-Induced “Rebound Immune Suppression” by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- 1 July 2019
- journal article
- research article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 104 (4) , 903-912
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81402520)
- Susan and Peter Goodwin Foundation
- Mabuchi Research fund
- Orr Family Foundation
- Wiegand Foundation
- MD Anderson
- Lung Cancer Research Foundation
- Cancer Center Support (CA016672)
- National Cancer Institute
- University of Texas MD Anderson Cancer Center
This publication has 35 references indexed in Scilit:
- Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cellsCancer Immunology, Immunotherapy, 2013
- Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T CellsScience Translational Medicine, 2013
- Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancerBlood, 2013
- CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate CancerCancer Research, 2013
- Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancerOncoImmunology, 2013
- Recruitment of Myeloid but not Endothelial Precursor Cells Facilitates Tumor Regrowth after Local IrradiationCancer Research, 2010
- Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancerLung Cancer, 2010
- Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing TumorsMolecular Cancer Therapeutics, 2010
- Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatmentBlood, 2009
- Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma ModelJournal of Medicinal Chemistry, 2009